AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer - Concepedia

Concepedia

Publication | Open Access

AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

DOI Full Paper Access

220

Citations

40

References

2020

Year

Michael J. Giffin, Keegan S. Cooke, Edward K. Lobenhofer, Juan Estrada, Jinghui Zhan, Petra Deegen, Melissa Thomas, Christopher M. Murawsky, Jonathan Werner, Siyuan Liu,

Clinical Cancer Research

Abstract

AMG 757 has a compelling safety and efficacy profile in preclinical studies making it a viable option for targeting DLL3-expressing SCLC tumors in the clinical setting.

References

	Year	Citations

Page 1